PGGM Investments Acquires 51,900 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• PGGM Investments increased its stake in Regeneron Pharmaceuticals by 159.7%, acquiring an additional 51,900 shares during the 2nd quarter, resulting in ownership of approximately 0.08% of the company.
• Regeneron recently reported $12.89 EPS for the quarter, exceeding analysts' expectations, and generated revenues of $3.68 billion, up 3.6% year-over-year.
• The company has been rated largely positively by analysts, with multiple upgrades, and currently holds an average rating of "Moderate Buy" with a consensus price target of $817.67.

PGGM Investments boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 159.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 84,397 shares of the biopharmaceutical company's stock after buying an additional 51,900 shares during the period. PGGM Investments owned approximately 0.08% of Regeneron Pharmaceuticals worth $44,308,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in REGN. Nuveen LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $343,764,000. Pacer Advisors Inc. increased its position in Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after buying an additional 390,374 shares during the period. Assenagon Asset Management S.A. increased its position in Regeneron Pharmaceuticals by 171.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after buying an additional 303,785 shares during the period. Goldman Sachs Group Inc. increased its position in Regeneron Pharmaceuticals by 18.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after buying an additional 174,056 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after purchasing an additional 121,545 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on REGN shares. Citigroup reissued a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Redburn Atlantic raised Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Raymond James Financial raised Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Finally, Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $562.27 on Wednesday. The stock's fifty day simple moving average is $570.12 and its 200 day simple moving average is $568.72. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm has a market cap of $59.59 billion, a price-to-earnings ratio of 14.17, a P/E/G ratio of 1.79 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,061.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business's revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $11.56 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.